Rate My Professor Nikhil Aggarwal

Aggarwal has contributed to numerous peer-reviewed publications in the field. Notable works include the 2022 review “Microbiome and human health: Current understanding, engineering, and enabling technologies” published in Chemical Reviews, the 2017 article “Designer probiotics for the prevention and treatment of human diseases” in Current Opinion in Chemical Biology, the 2020 paper “Engineering probiotics for therapeutic applications: recent examples and translational outlook” in Current Opinion in Biotechnology, the 2025 study “Engineered commensals for targeted nose-to-brain drug delivery” in Cell, the 2024 article “Microbial engineering strategies to utilize waste feedstock for sustainable bioproduction” in Nature Reviews Bioengineering, and the 2026 paper “Engineered commensals for metabolic modulation of the gut-liver-brain axis” in Cell. He is also a co-author on works such as “Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy” in Nature Communications (2024) and “FELICX: A robust nucleic acid detection method using flap endonuclease and CRISPR-Cas12” in Biosensors and Bioelectronics (2023). His contributions support advancements in programmable microbial therapies and metabolic modulation using engineered commensals.